Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis
Authors:
- 1 July 2008
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 52 (7) , 2486-2496
Abstract
Simulating the average non-protein-bound (free) human serum drug concentration-time profiles for linezolid in an in vitro pharmacodynamic model, we characterized the pharmacodynamic parameter(s) of linezolid predictive of kill and for prevention of resistance in Bacillus anthracis . In 10-day dose-ranging studies, the average exposure for ≥700 mg of linezolid given once daily (QD) resulted in >3-log CFU/ml declines in B. anthracis without resistance selection. Linezolid at ≤600 mg QD amplified for resistance. With twice-daily (q12h) dosing, linezolid at ≥500 mg q12 h was required for resistance prevention. In dose fractionation studies, killing of B. anthracis was predicted by the area under the time-concentration curve (AUC)/MIC ratio. However, resistance prevention was linked to the maximum serum drug concentration ( C max )/MIC ratio. Monte Carlo simulations predicted that linezolid at 1,100 mg QD would produce in 96.7% of human subjects a free 24-h AUC that would match or exceed the average 24-h AUC of 78.5 mg·h/liter generated by linezolid at 700 mg QD while reproducing the shape of the concentration-time profile for this pharmacodynamically optimized regimen. However, linezolid at 700 mg q12h (cumulative daily dose of 1,400 mg) would produce an exposure that would equal or exceed the average free 24-h AUC of 90 mg·h/liter generated by linezolid at 500 mg q12h in 93.8% of human subjects. In conclusion, in our in vitro studies, the QD-administered, pharmacodynamically optimized regimen for linezolid killed drug-susceptible B. anthracis and prevented resistance emergence at lower dosages than q12h regimens. The lower dosage for the pharmacodynamically optimized regimen may decrease drug toxicity. Also, the QD administration schedule may improve patient compliance.Keywords
This publication has 30 references indexed in Scilit:
- Impact of Resistance Selection and Mutant Growth Fitness on the Relative Efficacies of Streptomycin and Levofloxacin for Plague TherapyAntimicrobial Agents and Chemotherapy, 2007
- Isoniazid Bactericidal Activity and Resistance Emergence: Integrating Pharmacodynamics and Pharmacogenomics To Predict Efficacy in Different Ethnic PopulationsAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro ModelAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey ModelAntimicrobial Agents and Chemotherapy, 2006
- Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex PatientsAntimicrobial Agents and Chemotherapy, 2006
- Effective Antimicrobial Regimens for Use in Humans for Therapy ofBacillus anthracisInfections and Postexposure ProphylaxisAntimicrobial Agents and Chemotherapy, 2005
- Bacterial‐Population Responses to Drug‐Selective Pressure: Examination of Garenoxacin's Effect onPseudomonas aeruginosaThe Journal of Infectious Diseases, 2005
- Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United StatesEmerging Infectious Diseases, 2001
- Index Case of Fatal Inhalational Anthrax Due to Bioterrorism in the United StatesNew England Journal of Medicine, 2001
- Antibiotic Effects on Bacterial Viability, Toxin Production, and Host ResponseClinical Infectious Diseases, 1995